Patent ID: 11873348
Assignee: ALLIGATOR BIOSCIENCE AB
Field: Biotechnology (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method for the treatment of a cancer and/or a tumour in a subject, comprising the step of administering to the subject an effective amount of a bispecific antibody, wherein said bispecific antibody comprises a first binding domain, designated B1, which is capable of binding specifically to CD40, and a second binding domain, designated B2, which is capable of specifically binding to carcinoembryonic antigen (CEA),
wherein binding domain B1 comprises the three CDRs of the heavy chain and the three CDRs of the light chain of antibody ffAC 05337 (SEQ ID NOs: 81, 82 and 83; and SEQ ID NO: 96, GNI, and SEQ ID NO: 98); and
wherein binding domain B2 comprises the three CDRs of the heavy chain and the three CDRs of the light chain of antibody ffAC 05337 (SEQ ID NOs: 216, 217 and 239 and SEQ ID NO: 90, AAS, and SEQ ID NO: 311).